Acrivon Therapeutics Inc (ACRV)
7.55
0.00 (0.00%)
USD |
NASDAQ |
Jun 13, 12:50
Acrivon Therapeutics Enterprise Value: 123.15M for June 12, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 12, 2024 | 123.15M |
| June 11, 2024 | 118.51M |
| June 10, 2024 | 123.45M |
| June 07, 2024 | 113.88M |
| June 06, 2024 | 116.66M |
| June 05, 2024 | 118.21M |
| June 04, 2024 | 115.74M |
| June 03, 2024 | 127.78M |
| May 31, 2024 | 128.39M |
| May 30, 2024 | 123.76M |
| May 29, 2024 | 121.60M |
| May 28, 2024 | 128.39M |
| May 24, 2024 | 135.50M |
| May 23, 2024 | 140.44M |
| May 22, 2024 | 154.64M |
| May 21, 2024 | 143.52M |
| May 20, 2024 | 154.02M |
| May 17, 2024 | 164.52M |
| May 16, 2024 | 154.33M |
| May 15, 2024 | 157.11M |
| May 14, 2024 | 148.16M |
| May 13, 2024 | 151.86M |
| May 10, 2024 | 160.82M |
| May 09, 2024 | 141.36M |
| May 08, 2024 | 144.13M |
| Date | Value |
|---|---|
| May 07, 2024 | 147.53M |
| May 06, 2024 | 162.66M |
| May 03, 2024 | 186.12M |
| May 02, 2024 | 151.23M |
| May 01, 2024 | 144.13M |
| April 30, 2024 | 170.68M |
| April 29, 2024 | 198.78M |
| April 26, 2024 | 151.23M |
| April 25, 2024 | 151.54M |
| April 24, 2024 | 183.34M |
| April 23, 2024 | 193.22M |
| April 22, 2024 | 183.65M |
| April 19, 2024 | 179.92M |
| April 18, 2024 | 215.42M |
| April 17, 2024 | 209.25M |
| April 16, 2024 | 182.39M |
| April 15, 2024 | 186.71M |
| April 12, 2024 | 198.44M |
| April 11, 2024 | 176.83M |
| April 10, 2024 | 125.23M |
| April 09, 2024 | 107.80M |
| April 08, 2024 | 23.81M |
| April 05, 2024 | 36.72M |
| April 04, 2024 | 41.47M |
| April 03, 2024 | 40.79M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-61.52M
Minimum
Nov 21 2023
380.80M
Maximum
Feb 14 2023
103.31M
Average
122.04M
Median
Jul 17 2023
Enterprise Value Benchmarks
| MyMD Pharmaceuticals Inc | 3.117M |
| Vincerx Pharma Inc | 15.71M |
| Heron Therapeutics Inc | 653.86M |
| GlycoMimetics Inc | -14.33M |
| Immunic Inc | 16.19M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.49M |
| Total Expenses (Quarterly) | 17.67M |
| EPS Diluted (Quarterly) | -0.73 |
| Earnings Yield | -38.28% |